These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1653675)

  • 61. Myoblast transplantation.
    Furlong TE
    Science; 1992 Sep; 257(5075):1329. PubMed ID: 1529325
    [No Abstract]   [Full Text] [Related]  

  • 62. Immunological identification of a high molecular weight protein as a candidate for the product of the Duchenne muscular dystrophy gene.
    Kao L; Krstenansky J; Mendell J; Rammohan KW; Gruenstein E
    Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4491-5. PubMed ID: 3288996
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dystrophin assay in muscular dystrophies: an Indian experience.
    Jain S; Sarkar C; Dinda AK; Maheshwari MC
    Natl Med J India; 1993; 6(6):259-62. PubMed ID: 7950930
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Myoblast transplantation.
    Law PK
    Science; 1992 Sep; 257(5075):1329; author reply 1329-30. PubMed ID: 1529326
    [No Abstract]   [Full Text] [Related]  

  • 65. Antibody formation after myoblast transplantation in Duchenne-dystrophic patients, donor HLA compatible.
    Roy R; Tremblay JP; Huard J; Richards C; Malouin F; Bouchard JP
    Transplant Proc; 1993 Feb; 25(1 Pt 2):995-7. PubMed ID: 8442296
    [No Abstract]   [Full Text] [Related]  

  • 66. Duchenne muscular dystrophy immunohistochemistry of foetal muscles.
    Martin JJ; Ceuterick C; Lübke U; Van Broeckhoven C
    Acta Neurol Belg; 1993; 93(3):130-8. PubMed ID: 7688489
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Abnormal expression of dystrophin-associated proteins in Fukuyama-type congenital muscular dystrophy.
    Matsumura K; Nonaka I; Campbell KP
    Lancet; 1993 Feb; 341(8844):521-2. PubMed ID: 8094772
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin.
    Vilquin JT; Wagner E; Kinoshita I; Roy R; Tremblay JP
    J Cell Biol; 1995 Nov; 131(4):975-88. PubMed ID: 7490298
    [TBL] [Abstract][Full Text] [Related]  

  • 69. [Association between dystrophin and neuronal nitric oxide synthase in muscles of progressive muscular dystrophy].
    Wang S; Shen D
    Zhonghua Yi Xue Za Zhi; 2002 Feb; 82(3):155-7. PubMed ID: 11953148
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Detection of dystrophin with anti-peptide antibodies].
    Takeda A; Jimi T; Misugi N; Miyake S; Kumagai T; Nakamura Y; Wakayama Y
    Rinsho Byori; 1992 Sep; 40(9):953-8. PubMed ID: 1434031
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Myoblast therapy.
    Epstein HF; Fischman DA; Bader D; Changeux JP; Buckhold K; Ordahl CP; Hoffman E; Kedes LH; Konieczny S; Leinwand LA
    Science; 1992 Aug; 257(5071):738. PubMed ID: 1496388
    [No Abstract]   [Full Text] [Related]  

  • 72. Immunohistochemistry in the diagnosis of dystrophinopathies.
    Manole E
    Rom J Neurol Psychiatry; 1995; 33(1):51-5. PubMed ID: 7547371
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Abnormal localization of laminin subunits in muscular dystrophies.
    Hayashi YK; Engvall E; Arikawa-Hirasawa E; Goto K; Koga R; Nonaka I; Sugita H; Arahata K
    J Neurol Sci; 1993 Oct; 119(1):53-64. PubMed ID: 8246011
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Localization and characterization of dystrophin in muscle biopsy specimens from Duchenne muscular dystrophy and various neuromuscular disorders.
    Uchino M; Araki S; Miike T; Teramoto H; Nakamura T; Yasutake T
    Muscle Nerve; 1989 Dec; 12(12):1009-16. PubMed ID: 2695839
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts.
    Partridge TA; Morgan JE; Coulton GR; Hoffman EP; Kunkel LM
    Nature; 1989 Jan; 337(6203):176-9. PubMed ID: 2643055
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Monoclonal antibodies targeted against the C-terminal domain of dystrophin or utrophin.
    Fabbrizio E; Léger J; Anoal M; Léger JJ; Mornet D
    FEBS Lett; 1993 May; 322(1):10-4. PubMed ID: 8482362
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genetic and biochemical determinations in the pre-transplant workup and in the post-transplant assessment period.
    Worton RG; Bulman DE; Zubrzycka-Gaarn EE; Ray PN
    Adv Exp Med Biol; 1990; 280():219-25; discussion 225-6. PubMed ID: 2248141
    [No Abstract]   [Full Text] [Related]  

  • 79. [Muscle cultures and immunocytochemical study of dystrophin in patients with Duchenne muscular dystrophy and control patients].
    Watanabe Y; Yakata N; Wakai S; Oya K; Chiba S
    No To Hattatsu; 1992 Nov; 24(6):602-5. PubMed ID: 1419176
    [No Abstract]   [Full Text] [Related]  

  • 80. Dystrophin and nebulin in the muscular dystrophies.
    Patel K; Voit T; Dunn MJ; Strong PN; Dubowitz V
    J Neurol Sci; 1988 Nov; 87(2-3):315-26. PubMed ID: 3062133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.